Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Mr. Palash brings over 30 years of expertise in commercial operations in the healthcare industry to this new role at Gamida Cell, where he will be responsible for overseeing operational activities. Mr. Palash joins Gamida Cell from Protalix Biotherapeutics, Inc., where, as COO, he led all operational activities through the company’s approval by the U.S. Food and Drug Administration (FDA) of plant cell culture produced protein product, Elelyso®. Prior to joining Protalix, Mr. Palash served as a general manager at ColBar LifeScience Ltd., a biomaterial company acquired by Johnson & Johnson, where he led the planning, construction, scale-up and regulatory oversight of its Israel-based manufacturing facility. He also successfully led FDA audits for Evolence® and Ossix®, and was a member of the Global Aesthetic Management Team within the Consumer Group of Johnson & Johnson. Earlier in his career, Mr. Palash held operational roles at Teva Pharmaceutical Industries and Interpharm Laboratories.
Mr. Schick will lead the strategic planning and implementation of global market access and reimbursement initiatives. He joins Gamida Cell from Kite Pharma, where he served as senior director, payer relations, and was responsible for the development and implementation of tactical strategies to ensure appropriate access to cancer immunotherapy YESCARTA®. Prior to joining Kite, Mr. Schick served as a director at Infinity Pharmaceuticals, where he led the design, implementation and management of trade, distribution and physician network functions to support potential launch of the company’s hematology/oncology candidate. Mr. Schick has also held various roles at Onyx Pharmaceuticals, Otsuka America Pharmaceutical and Allergan.
“We are delighted to welcome Tzvi and John to the Gamida Cell team,” said Julian Adams, Ph.D., chairman and chief executive officer of Gamida Cell. “Their unique experiences in operations and market access will be strong assets to Gamida Cell as we continue to advance our clinical programs in blood cancers and rare hematologic diseases.”
About Gamida Cell
Gamida Cell is a clinical-stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is developing a diverse pipeline based on its nicotinamide-, or NAM, -based cell expansion technology, addressing limitations of current cell therapies to provide new treatment alternatives for patients. To learn more about Gamida Cell, including current clinical studies, please visit www.gamida-cell.com and on Twitter, LinkedIn and Facebook.
Source: Gamida Cell